



Ronnie Aronson MD, FRCPC, FACE

* Ronnie Aronson provides medical services through Dr. Ronnie Aronson Medicine Professional Corporation

Bayview #107 & 125 -1929 Bayview Avenue, Toronto, Ontario M4G 3E8, Canada

Tel (416) 645-2929

CURRICULUM VITAE

Education

Mar 2015	Advanced Cardiac Life Support (ACLS)	ACLS Certification Institute
1998	Fellowship	American College of Endocrinology
1995	Certification, Endocrinology & Metabolism	Royal College of Physicians Canada, American Board of Internal Medicine
1994	Fellowship, Internal Medicine	Royal College of Physicians Canada, American Board of Internal Medicine
1990	Doctor of Medicine	University of Toronto

Professional Activities

Oct2015-Present	Chief Medical Director	LMC Diabetes and Endocrinology
1997-2015	Executive Director	LMC Diabetes & Endocrinology
1995-2001	Staff Endocrinologist	Oakville Trafalgar Memorial Hospital

Publications

- Aronson R, Reznik Y, Conget I., et al. Sustained efficacy of insulin pump therapy, compared with multiple daily injections, in type 2 diabetes: 12-month data from the Opt2mise randomized trial. *Diabetes Obes Metab* 2016. In press. DOI: 10.1111/dom.1264
- Aronson R. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. *Curr Med Res Opin* 2015;31:901-11
- Aronson R. The Functionally Refractory Patient in Diabetes – Prevalence and Predictors within Specialist Care Registries. *US Endocrinology* 2015;11(1):30-1
- Aronson R, Orzech N, Ye C, Goldenberg R, Brown V. Specialist-led Diabetes Registries and Predictors of Poor Glycemic Control in Type 2 Diabetes: Insights into the Functionally Refractory Patient from the LMC Diabetes Registry Database. *J Diabetes* 2015. Published online 24 Mar 2015 doi: 10.1111/1753-0407.12257
- Reznik Y, Cohen O, Aronson R. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (Opt2mise): a randomised open-label controlled trial. *Lancet* 2014;384:1265-72.
- Aronson R, Cohen O, Conget I et al. Opt2mise: A randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes – research design and methods. *Diabetes Technology & Therapeutics* 2014;16:414-20.
- Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozziilli P. Low-dose otelexizumab anti-CD3 monoclonals antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 2 diabetes. *Diabetes Care* 2014;37:2746-54.
- Hanefeld M, Berria R, Lin J, Aronson R et al. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. *Adv Ther* 2014;31:861-872
- Ahren B, Gaultier JF, Berria R, Stager W, Aronson R, Bailey CJ. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab* 2014;16:861-868..
- Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, et al. *Circulation* 2014;129:999-1008
- Aronson R, Gibney MA, Oza K, Berube J, Kassler-Taub K, Hirsch L. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. *Clin Ther* 2013;35:923-933
- Aronson R. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of type 2 diabetes. *Expert Rev. Clin. Pharmacol* 2013;6(6) :603-612
- Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). *Diabetes Obes Metab* 2013;15:1000-1007
- Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ling L, Ye J, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin (GetGoal-L). *Diabetes Care* 2013;36:2489-2496
- Riddle M, Souhami E, Forst T, Silvestre L, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine (GETGOAL-DUO-1). *Diabetes Care* 2013;36:2497-2503
- Aronson R. The role of comfort and discomfort in insulin therapy. *Diabetes Technology & Therapeutics* 2012;14(8):741-747
- Ahren B, Leguizamo A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide one-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). *Diabetes Care* 2013;36:2543-2550
- Swinnen SG, Dain M-P, Aronson R, et al. A 24-week randomized Treat-to-Target Trial. *Diabetes Care* 2010;33(6)
- Aronson R, et al. Obesity Research. 2001; 9 (Supp 3):85S.
- Aronson R, Offman HJ, Joffe R, Naylor CD. *Archives General Psychiatry* 1996; 53: 842-848.
- Aronson R, Sochett E, Pearl RH, Daneman A, Thorner P, Daneman D. *J Ped Endocrinology & Metabolism* 1996;9(6)

Clinical Trials & Research Activities

2016-Present	B1521022(Pfizer), B1481022(Pfizer), B1481038(Pfizer), APD35-G000-401(Eisai), MK8835-002(Merck), EFC12404/405(Sanofi-aventis), B1481045 (Pfizer), NN9211-3919(Novo Nordisk), EFC13799(Sanofi-aventis), HARMONY 10(GSK), CREDENCE(Janssen Research), J&J 2004(Janssen Research), STRENGTH(AstraZeneca), LX4211.309(Lexicon), PERL(Joslin Diabetes), BDT-SMART02 (BD Technologies), LX4211.312 (Lexicon), DERIVE (AstraZeneca), NN9828-4150 (Novo Nordisk), B4801010 (Pfizer), DIAMOND (Dexcom), REMIT (PHRI) FIT (LMC Diabetes), etc.
--------------	---



Ronnie Aronson MD, FRCPC, FACE

*** Ronnie Aronson provides medical services through Dr. Ronnie Aronson Medicine Professional Corporation**

Bayview #107 & 125 -1929 Bayview Avenue, Toronto, Ontario M4G 3E8, Canada

Tel (416) 645-2929

1997-2015

264 Clinical Trials – sponsors including Pfizer, Novo Nordisk Boehringer Ingelheim, Sanofi, GSK, Takeda, Eli Lilly, Roche, Novartis, AstraZeneca, Bristol-Myers Squibb